

Request for Application (RFA) – Reissuance  
**NCI Community Oncology Research  
Program**

*Brandy Heckman-Stoddard, PhD, MPH  
Acting Director NCORP*


*Kate Castro, PhD  
Acting Scientific Director CCCR*

*In collaboration with the Divisions of Cancer Treatment & Diagnosis & the Center to Cancer Health Equity*

# NCORP Objectives

- Design and conduct clinical trials/human subject studies for adults and children in cancer prevention and control and cancer care delivery, quality-of-life studies embedded within treatment trials;
- Incorporate the needs of diverse populations into studies and takes steps to enhance participation of these groups;
- Enhance patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);
- Integrate cancer disparities research within the community network.
- Understand and address cancer care delivery challenges in the community; and
- Disseminate knowledge gained from trials throughout the community.

# Current NCORP Infrastructure



# NCORP Growth 2019-2024

Metric	2019	2024 (8/27/2024)	% increase
Number of physicians	4,104	4,274	4%
Number of non-physician investigators	309	1,292	418%
Registered Research Staff	4,399	4,791	9%
Number of Affiliate and sub-affiliate sites	990	1,019	3%
Number of Affiliate and sub affiliate sites that accrued to CPC and Treatment Trials	565	685	21%
Treatment Accrual	3,298	3,531	7%
Cancer Prevention and Control Accrual (including TMIST)	15,690	22,831	46%
Qualify as High Performance Site (>200 accruals)	15	21	40%
Number of Affiliate and sub-Affiliate Sites that participated in CCDR Trials	351	559	59%

# Proposed Improvements without Budgetary Impact

- Change M/U to MUR and Increase the Minority or Rural % required by MUR Sites to 40% combined catchment
- Require a trial-specific recruitment and retention plans
- Require plain language summaries with protocol submission
- Enhanced tracking of OEWG timelines
- Enhanced tracking of slow accruing trials and amendment timelines
- Restructure RPPR submission to collect outcomes and understand workload

# Proposed Improvements with Budget Impact

- Fund increased per case reimbursement consistent with NCTN
- Fund the expansion of the NCORP affiliate and sub-affiliate network so it can accrue at its full potential including staffing for CCCR
- Re-evaluate High Performance status (>200 accrual per year) every 2 years
- Fund increased per case reimbursement to Lead Academic Participating Sites for accrual to CPC trials meeting high performance metrics
- Workforce Development
- Create a linkage within the NCTN biobanks with QoL data to study symptom mechanisms

# Proposed Expansion with Budgetary Impact

- Fund the FY 2026 program for 7 years instead of 6 to create separation between the NCTN and NCORP. Future NCORP RFAs will return to 6 years.
- Allow limited Research Base Member Site participation in CCCR trials
- Fund ePRO contract to support remote data capture and enhanced data sharing

# NCORP Budget Request (in \$ Millions)

	FY24	FY25 extension	Proposed Increase	\$ increase(M)	FY26-32
Community Sites/ MR Sites (UG1)	69.7	73	25% increase dedicated to support patient accrual including treatment accrual reimbursement rate; 25% increase in CPC patient reimbursement; 37.5% staffing at affiliate and sub-affiliate sites including high performance transitions; 12.5% CCDR	20	93
Research Base (UG1)	44.64	47.4	Increase in staff support to protocol development, stats, translation, and data sharing; increase in non-NCORP Site capitation	7.6	55
U24 supplements	3.3	3.3	Increase for the biobanks	.7	4
Contract Funding (including NCTN Centralized Functions)	8.925	8.925	Re-competition increases; Electronic PRO capture system in place for use with increased expense and data sharing.	4	13
<b>Total Cost</b>	<b>126.565</b>	<b>132.625</b>		<b>32.375</b>	<b>165</b>
<b>% increase</b>					<b>24.7%</b>



# BSA Committee Review and Feedback

- MUR change
  - How to address potential overlap in these populations?
  - Definition of Rural
  - Change in Race definition for 2030 Census
- High-performance site
- Workforce development
- Community Engagement
- Prevention portfolio expansion

# Honoring Dr. McCaskill Stevens



**Worta McCaskill-Stevens, M.D., M.S.**

**NCORP Director**

**PAR-24-153 (K12)**

## New Funding Opportunity

NCI Worta McCaskill-Stevens  
Career Development Award  
for Community Oncology and  
Prevention Research



**NATIONAL  
CANCER  
INSTITUTE**

[www.cancer.gov](http://www.cancer.gov)

[www.cancer.gov/espanol](http://www.cancer.gov/espanol)